Vi­a­tris and Bio­con mull pool­ing their biosim­i­lars in­to a $10B stand­alone com­pa­ny — re­port

Vi­a­tris (My­lan/Pfiz­er’s Up­john) and In­dia’s Bio­con Bi­o­log­ics are re­port­ed­ly pon­der­ing whether to fur­ther en­twine their biosim­i­lar busi­ness­es in­to a $10 bil­lion stand­alone com­pa­ny, ac­cord­ing to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER